HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Acetyl-cholinesterase-inhibitors slow cognitive decline and decrease overall mortality in older patients with dementia.

Abstract
We evaluated the effect of Acetyl-cholinesterase-inhibitors (AChEIs) on cognitive decline and overall survival in a large sample of older patients with late onset Alzheimer's disease (LOAD), vascular dementia (VD) or Lewy body disease (LBD) from a real world setting. Patients with dementia enrolled between 2005 and 2020 by the "Alzheimer's Disease Research Centers" were analysed; the mean follow-up period was 7.9 years. A 1:1 propensity score matching was performed generating a cohort of 1.572 patients (786 treated [AChEIs +] and 786 not treated [AChEIs-] with AChEIs. The MMSE score was almost stable during the first 6 years of follow up in AChEIs + and then declined, while in AChEIs- it progressively declined so that at the end of follow-up (13.6 years) the average decrease in MMSE was 10.8 points in AChEIs- compared with 5.4 points in AChEIs + (p < 0.001). This trend was driven by LOAD (Δ-MMSE:-10.8 vs. -5.7 points; p < 0.001), although a similar effect was observed in VD (Δ-MMSE:-11.6 vs. -8.8; p < 0.001). No effect on cognitive status was found in LBD. At multivariate Cox regression analysis (adjusted for age, gender, dependency level and depression) a strong association between AChEIs therapy and lower all-cause mortality was observed (H.R.:0.59; 95%CI: 0.53-0.66); this was confirmed also in analyses separately conducted in LOAD, VD and LBD. Among older people with dementia, treatment with AChEIs was associated with a slower cognitive decline and with reduced mortality, after a mean follow-up of almost eight years. Our data support the effectiveness of AChEIs in older patients affected by these types of dementia.
AuthorsMarco Zuin, Antonio Cherubini, Stefano Volpato, Luigi Ferrucci, Giovanni Zuliani
JournalScientific reports (Sci Rep) Vol. 12 Issue 1 Pg. 12214 (07 16 2022) ISSN: 2045-2322 [Electronic] England
PMID35842477 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Copyright© 2022. The Author(s).
Chemical References
  • Cholinesterase Inhibitors
  • Cholinesterases
Topics
  • Aged
  • Alzheimer Disease (psychology)
  • Cholinesterase Inhibitors (therapeutic use)
  • Cholinesterases
  • Cognitive Dysfunction (chemically induced, drug therapy)
  • Humans
  • Lewy Body Disease

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: